Avadel Pharmaceuticals - AVDL Stock Forecast, Price & News

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Avadel Pharmaceuticals Stock Performance

Shares of Avadel Pharmaceuticals stock traded down $0.06 on Monday, hitting $6.87. 617,734 shares of the company traded hands, compared to its average volume of 1,976,978. The firm's 50-day simple moving average is $3.91 and its 200 day simple moving average is $5.21. The company has a debt-to-equity ratio of 2.11, a quick ratio of 2.72 and a current ratio of 2.72. Avadel Pharmaceuticals has a 12-month low of $1.05 and a 12-month high of $11.59.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Rating) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.60). During the same quarter in the previous year, the firm posted ($0.33) EPS. On average, analysts expect that Avadel Pharmaceuticals will post -1.76 EPS for the current year.

Analysts Set New Price Targets

AVDL has been the topic of several recent analyst reports. Jefferies Financial Group cut shares of Avadel Pharmaceuticals from a "buy" rating to a "hold" rating and increased their target price for the stock from $6.00 to $8.00 in a research note on Wednesday, August 10th. Needham & Company LLC increased their target price on shares of Avadel Pharmaceuticals from $6.00 to $9.00 and gave the stock a "buy" rating in a research note on Wednesday, August 10th. SVB Leerink increased their target price on shares of Avadel Pharmaceuticals from $6.00 to $12.00 and gave the stock an "outperform" rating in a research note on Thursday. Craig Hallum lowered their target price on shares of Avadel Pharmaceuticals from $15.50 to $12.00 and set a "buy" rating on the stock in a research note on Thursday, July 28th. Finally, Stifel Nicolaus increased their target price on shares of Avadel Pharmaceuticals from $2.00 to $5.00 in a research note on Tuesday, July 19th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $10.29.

Insider Buying and Selling

In other Avadel Pharmaceuticals news, CFO Thomas S. Mchugh bought 50,000 shares of the firm's stock in a transaction that occurred on Friday, May 27th. The shares were bought at an average price of $2.14 per share, for a total transaction of $107,000.00. Following the transaction, the chief financial officer now directly owns 71,500 shares in the company, valued at $153,010. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Avadel Pharmaceuticals news, Director Eric J. Ende bought 15,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 31st. The shares were bought at an average price of $2.16 per share, for a total transaction of $32,400.00. Following the transaction, the director now directly owns 114,900 shares in the company, valued at $248,184. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Thomas S. Mchugh bought 50,000 shares of the firm's stock in a transaction that occurred on Friday, May 27th. The stock was acquired at an average price of $2.14 per share, for a total transaction of $107,000.00. Following the transaction, the chief financial officer now owns 71,500 shares in the company, valued at $153,010. The disclosure for this purchase can be found here. Insiders have acquired a total of 75,000 shares of company stock worth $155,400 in the last 90 days. 3.20% of the stock is owned by company insiders.